Uses of Brocast 10: - Asthma prevention - Sneezing and runny nose due to allergies Asthma, Allergic rhinitis Hypersensitivity.

Antibodies to leukotriene receptors

The arachidonic acid metabolism results in the production of cysteinyl leukotrienes (LTC4, LTD4, and LTE4) from a variety of cells, including mast cells and eosinophils. Cysteinyl leukotriene receptors (CysLT) are located in the human airway, and these eicosanoids bind to them. The orally active drug montelukast has a strong affinity and specificity for the CysLT1 receptor. Without any agonist activity, it inhibits LTD4's physiological effects at the CysLT1 receptor.

How to use Montelukast: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Montelukast may be taken with or without food, but it is better to take it at a fixed time. Adult Dose: Oral Chronic asthma Adult: As film-coated tab: 10 mg once daily in the evening. Allergic rhinitis Adult: 10 mg once daily. Prophylaxis of exercise-induced asthma Adult: 10 mg at least 2 hr prior to exercise; do not take additional doses w/in 24 hr. Elderly: No dosage adjustment needed. Hepatic impairment: Mild to moderate: No dosage adjustment needed. Child Dose: Asthma Prophylaxis and maintenance treatment in patients aged >12 months <12 months: Safety and efficacy not established 12-24 months: 4 mg (granules) PO once daily in evening 2-6 years: 4 mg (chewable tablet or granules) PO once daily in evening 6-15 years: 5 mg (chewable tablet) PO once daily in evening >15 years: 10 mg (conventional tablet) PO once daily in evening Exercise-Induced Bronchospasm Prophylaxis 6-15 years: 5 mg (chewable tablet) PO 2 hours before exercise; do not take additional dose within 24 hours >15 years: 10 mg PO 2 hours before exercise; do not take additional dose within 24 hours If taking drug for another indication, do not take additional dose to prevent EIB Perennial Allergic Rhinitis <6 months: Safety and efficacy not established 6-24 months: 4 mg (granules) PO once daily 2-6 years: 4 mg (chewable tablet or granules) PO once daily 6-15 years: 5 mg (chewable tablet) PO once daily >15 years: 10 mg (conventional tablet) PO once daily Seasonal Allergic Rhinitis <2 years: Safety and efficacy not established 2-6 years: 5 mg (chewable tablet) or 4 mg (granules) PO once daily 6-15 years: 5 mg (chewable tablet) PO once daily >15 years: 10 mg (conventional tablet) PO once daily Renal Dose: Renal impairment: No dosage adjustment needed.

Induced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).

Hypersensitivity.

Common - Nausea - Vomiting - Headache - Diarrhea >10% Headache (18.4%; similar to placebo) 1-10% >2% Abdominal pain,Eczema,Influenza,Laryngitis,Pharyngitis,Viral infection,Wheezing,Dental pain,Dizziness,Dyspepsia, Dental pain (2%),Dizziness (2%),Dyspepsia (2%)Elevated liver function tests (2%),Fever (2%),Gastroenteritis (2%),Nasal congestion (2%),Otitis (2%),Rash (2%),Urticaria (2%), >1% Bronchitis,Cough,Sinusitis,Upper respiratory tract infection <1% Allergic granulomatous angiitis (Churg-Strauss syndrome; rare),Cholestatic hepatitis (rare),Aggressive behavior, altered behavior, suicidal thoughts Potentially Fatal: Anaphylaxis, Churg-Strauss syndrome.

Montelukast is classified as pregnancy category B. Although it has been demonstrated that the medication crosses the placenta of pregnant rats and rabbits, there are no records of its use in pregnant humans. Although there is some evidence that it is also secreted in breast milk, little is known about the implications of this discovery. Before starting the therapy in nursing moms, caution should be exercised.

Precaution: Not for the relief of acute bronchospasm. Not to be used as monotherapy for the prevention of exercise-induced bronchospasm. Patients in whom asthma is precipitated by aspirin or other NSAIDs should continue to avoid aspirin and NSAIDs. Do not abruptly substitute for oral or inhaled corticosteroids. Be alert for any signs of Churg-Strauss syndrome. Pregnancy and lactation. Children <6 mth. Lactation: Unknown whether agent is excreted in breast milk, use with caution

The majority of overdose reports did not include any negative experiences. The most frequent side effects, which were in line with Montelukast's safety profile, were nausea, vomiting, psychomotor hyperactivity, thirst, headache, and stomach pain. In the case of an overdose, it is permissible to take the customary supportive measures, such as removing any unabsorbed material from the digestive tract, using clinical monitoring, and if necessary, instituting supportive therapy.

Store below 30°C in a cool, dry environment while keeping out light and moisture. Keep out of children's reach.

Leukotriene receptor antagonists

Montelukast is a selective leukotriene receptor antagonist that blocks the effects of cysteinyl leukotrienes in the airways.

After oral administration, montelukast passes the placenta in rats and rabbits. Nevertheless, there isn't any good, controlled research on pregnant women. Because the human reaction to medications is not usually predicted by research on animal reproduction, pregnant women should only use it if absolutely necessary. When giving the pill to a nursing mother, care should be taken because many medications are secreted in human milk.